DelveInsight has launched a new report on Bronchiolitis Obliterans Syndrome Pipeline
Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the primary factor limiting long-term transplant survival. It is characterized by progressive airflow obstruction resulting in acute rejection of the graft, followed by infections, or other coexistent condition.
Request for free sample copy- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-pipeline-insight
Bronchiolitis Obliterans Syndrome Pipeline analysis across different stages of development (Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities
Bronchiolitis Obliterans Syndrome Emerging Therapy
The expected launch of emerging therapy such as Liposomal Cyclosporine A (Zambon Pharma), Ruxolitinib (Incyte Corporation), Pirfenidone (Genentech) is expected to change the treatment landscape of Bronchiolitis Obliterans Syndrome (BOS) in the upcoming years.
Emerging drugs included in the report
Bronchiolitis Obliterans Syndrome Drugs
Bronchiolitis Obliterans Syndrome Treatment includes the use of Leukotriene Receptor Antagonist, Anti-Fibrotic Agents, Cell-cycle Inhibitors, Macrolide Antibiotics followed by Induction Therapies to avoid acute rejection at the time of transplantation.
Bronchiolitis Obliterans Syndrome Treatment
Despite rapid advances in the discipline of lung transplantation and demonstrable improvement in short-term outcomes, there has been no substantial decrease in the prevalence of BOS, and no effective treatment has yet been established. This results into BOS being the principal factor contributing to limited long-term survival and suboptimal quality of life among lung allograft recipients and represents a major scientific challenge that must be surmounted before lung transplantation can become a durable, curative therapy for patients with advanced lung disease.
Bronchiolitis Obliterans Syndrome Report Highlights
Table of content
What are the key questions answered?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/